Safety and Target Engagement of Complement C1q Inhibitor ANX007 in Neurodegenerative Eye Disease

Safety and Target Engagement of Complement C1q Inhibitor ANX007 in Neurodegenerative Eye Disease

Purpose: Complement C1q, the initiating molecule of the classical complement cascade, is involved in synapse elimination and neuronal loss in neurodegenerative diseases including glaucoma. Here we report an evaluation of the safety, tolerability, and ocular pharmacokinetics (PK) and pharmacodynamics...

Full description

Bibliographic Details
Main Authors: Yang Sun, MD, PhD, David Wirta, MD, Wendy Murahashi, MD, Vidhu Mathur, PhD, Sethu Sankaranarayanan, PhD, Lori K. Taylor, PhD, Ted Yednock, PhD, Donald S. Fong, MD, MPH, Jeffrey L. Goldberg, MD, PhD
Format: Article
Language:English
Published: Elsevier 2023-06-01
Series:Ophthalmology Science
Subjects:
ANX007
C1q
Classical complement pathway
Glaucoma
Intravitreal injection
Online Access:http://www.sciencedirect.com/science/article/pii/S2666914523000222

Internet

http://www.sciencedirect.com/science/article/pii/S2666914523000222

Similar Items